<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04716634</url>
  </required_header>
  <id_info>
    <org_study_id>BGB-A317-fruquintinib-201</org_study_id>
    <nct_id>NCT04716634</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors</brief_title>
  <official_title>A Multicenter, Open-label Phase 2 Study to Evaluate the Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Patients With Selected Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hutchison Medipharma Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>BeiGene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, multicenter, Phase 2 study designed to assess the efficacy and safety&#xD;
      of tislelizumab in combination with fruquintinib in participants with advanced or metastatic,&#xD;
      unresectable gastric cancer (GC), or colorectal cancer (CRC) or Non-small Cell Lung Cancer&#xD;
      (NSCLC). The study will be conducted in 2 parts. Part 1 will be the safety run-in stage to&#xD;
      determine dose-limiting toxicity (DLT) and recommended Phase 2 dose (RP2D). Part 2 will&#xD;
      assess the preliminary efficacy of tislelizumab in combination with fruquintinib in&#xD;
      participants as measured by the overall response rate (ORR) and other efficacy and safety&#xD;
      profiles.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label, multicenter, Phase 2 study designed to assess the efficacy and safety&#xD;
      of tislelizumab in combination with fruquintinib in patients with advanced or metastatic,&#xD;
      unresectable GC, and CRC or NSCLC. The study will be conducted in 2 parts.&#xD;
&#xD;
      Part 1 of the study will be the safety run-in stage which assesses dose-limiting toxicities&#xD;
      (DLTs) and RP2D. Part 2 will begin at RP2D. Patients enrolled in Part 1 at RP2D will be&#xD;
      counted towards Part 2; up to approximately 30 patients per cohort will be enrolled at RP2D.&#xD;
&#xD;
      The primary outcome measure of the study is ORR as assessed by the investigator per RECIST&#xD;
      v1.1. Tislelizumab and fruquintinib will be administered until disease progression,&#xD;
      intolerable toxicity, death, withdrawal of consent or until the study terminates.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 19, 2021</start_date>
  <completion_date type="Anticipated">August 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 15, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1 - Adverse Event (AE)</measure>
    <time_frame>Up to 28 Days in Part 1</time_frame>
    <description>Assessed per NCI-CTCAE v5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 - RP2D Of Fruquintinib In Combination With Tislelizumab</measure>
    <time_frame>Up to 28 Days in Part 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 - Objective Response Rate (ORR)</measure>
    <time_frame>through study completion, an average of 3 years</time_frame>
    <description>Assessed per RECIST v1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 2 - Progression-Free Survival (PFS)</measure>
    <time_frame>through study completion, an average of 3 years</time_frame>
    <description>Assessed per RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 - Disease Control Rate (DCR)</measure>
    <time_frame>through study completion, an average of 3 years</time_frame>
    <description>Assessed per RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 - Clinical Benefit Rate (CBR)</measure>
    <time_frame>through study completion, an average of 3 years</time_frame>
    <description>Assessed per RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 - Duration Of Response (DOR)</measure>
    <time_frame>through study completion, an average of 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 - Overall Survival (OS)</measure>
    <time_frame>through study completion, an average of 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 - Adverse Event</measure>
    <time_frame>through study completion, an average of 3 years</time_frame>
    <description>Assessed per NCI-CTCAE v5.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Tislelizumab + Fruquintinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with one of the tumors will be enrolled: GC,CRC and NSCLC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tislelizumab</intervention_name>
    <description>Tislelizumab is a humanized, immunoglobulin G4 (IgG4)-variant monoclonal antibody against PD 1.</description>
    <arm_group_label>Tislelizumab + Fruquintinib</arm_group_label>
    <other_name>BGB-A317</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fruquintinib</intervention_name>
    <description>Fruquintinib is a potent, oral VEGFR tyrosine kinase inhibitor (TKI)</description>
    <arm_group_label>Tislelizumab + Fruquintinib</arm_group_label>
    <other_name>HMPL-013</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent form (ICF) and able to comply with study requirements.&#xD;
&#xD;
          2. At least 1 measurable lesion as defined by RECIST v1.1.&#xD;
&#xD;
          3. Tumor tissue (archival tumor tissues as formalin-fixed paraffin-embedded blocks or&#xD;
             approximately 15 unstained slides) for central laboratory assessment&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) Performance Status â‰¤1&#xD;
&#xD;
          5. Histologically or cytologically confirmed, advanced or metastatic, unresectable&#xD;
             adenocarcinoma of gastric or esophagogastric junction or colon or rectum, and&#xD;
             histologically or cytologically confirmed, locally advanced (Stage IIIB) not amenable&#xD;
             to curative surgery or radiotherapy, or metastatic (Stage IV) NSCLC&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Has at screening any central nervous system metastasis and/or leptomeningeal disease.&#xD;
&#xD;
          2. Prior therapy targeting CTLA-4, PD-1, PD-L1 or programmed cell death protein ligand-2&#xD;
             (PD-L2) or any other antibody or drug specifically targeting T-cell costimulation or&#xD;
             checkpoint pathways.&#xD;
&#xD;
          3. Prior treatment with VEGFR-TKI or anti-VEGFR antibody (eg, ramucirumab).&#xD;
&#xD;
          4. Received more than 1 line of systemic treatment for advanced or metastatic,&#xD;
             unresectable adenocarcinoma of gastric or esophagogastric junction, or more than 2&#xD;
             lines of systemic treatment for advanced or metastatic, unresectable adenocarcinoma of&#xD;
             the colon or rectum, or prior systemic therapy for advanced or metastatic NSCLC.&#xD;
&#xD;
          5. Active autoimmune diseases or history of autoimmune diseases that may relapse, or&#xD;
             history of interstitial lung disease, noninfectious pneumonitis, or uncontrolled lung&#xD;
             diseases including but not limited to pulmonary fibrosis, acute lung diseases, etc.&#xD;
&#xD;
        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jian Li</last_name>
    <role>Study Director</role>
    <affiliation>BeiGene</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>BeiGene</last_name>
    <phone>1-877-828-5568</phone>
    <email>clinicaltrials@beigene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fujian Provincial Cancer Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350014</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital - Oncology</name>
      <address>
        <city>Haerbin</city>
        <state>Heilongjiang</state>
        <zip>150081</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Linyi Cancer Hospital</name>
      <address>
        <city>Linyi</city>
        <state>Shandong</state>
        <zip>276001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>West China Hospital ,Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 13, 2021</study_first_submitted>
  <study_first_submitted_qc>January 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 20, 2021</study_first_posted>
  <last_update_submitted>May 6, 2021</last_update_submitted>
  <last_update_submitted_qc>May 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

